吉西他滨联合热疗治疗晚期非小细胞肺癌64例临床研究

Clinical observation of thermotherapy combined with gemcitabine for patients with advanced non-small cell lung cancer

目的研究吉西他滨联合局部热疗治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法对2009年2月至2010年12月我院入院治疗的128例晚期非小细胞肺癌患者进行了研究,将128例患者随机分为2组,对照组患者采用吉西他滨化疗,21d为一个周期,两个周期为一个疗程;治疗组患者在对照组化疗基础上,联合局部热疗,一个疗程结束后评价治疗效果及不良反应。结果经过一个疗程的治疗,对照组治疗总有效率为25.0%,治疗组总有效率为43.8%,两组比较差异明显,有统计学意义(P<0.05);不良反应比较中,两组患者不良反应发生情况相当,差异无统计学意义(P>0.05)。结论吉西他滨联合局部热疗治疗晚期非小细胞肺癌临床效果显著,好于单一药物化疗,且不良反应发生情况与单药治疗无差异,值得临床推广应用。

Objective Study the clinical effect of local thermotherapy combined with gemcitabine in treatment of advanced NSCLC. Methods 128 patients with advanced NSCLC from Feb, 2009 to Dec, 2010 were randomly divided into treatment group and control group, the patients in control group were treated with gencitabine only, the patients in treatment group was received additionally with thermotherapy. 21 days for one cycle and two cycles were one course of treatment. Before treatment and after, clinical effect were observed and the side effect was compared. Results After treatment, the total effective ratio of treatment group was 43.8%, which was higher than control group （ 25.0% ）. The differences were statistically significant （ P 〈 0.05 ）, the clinical side effect of treatment group was equivalent to control group, there was no statistically significant be- tween the two groups （P 〉 0. 05 ） Conclusion Thermotherapy combined with gemcitabine had good effect in treatment of advanced NSCLC, which was better than gemcitabine only, it was worthy for clinical use.